MedPath

Effectiveness and safety assessment of add-on therapy of perampanel for epilepsy patients

Phase 3
Conditions
epilepsy syndromes
Registration Number
JPRN-UMIN000026880
Lead Sponsor
Juntendo University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1. Pregnancy patient 2. Simple partial seizure patient 3. Psychiatric unstable patient 4. Liver dysfunction patient 5. Alcoholic patient 6. Surgically treated patient

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change of seizure frequency. The number of seizure attack every 2 weeks will be monitored.
Secondary Outcome Measures
NameTimeMethod
A complete seizure reduction ratio, 50% reduction ratio, tolerability and EEG
© Copyright 2025. All Rights Reserved by MedPath